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Summary 
Rhesus monkeys were trained to discriminate injections 
of saline from those of 8-carboline-3-carboxylic acid ethyl 
ester (8-CCE), a compound that binds to the benzodiazepine 
receptor, but often has actions opposite to those of the 
benzodiazeplnes. A benzodlazepine agonist midazolam and low 
doses of a specific benzodiazepine antagonist, Ro 15-1788, 
reversed the discriminative effects of 8-CCE. Higher doses 
of Ro 15-1788 produced stimulus effects similar to ~-CCE. 
In a separate experiment, monkeys responded to terminate 
intravenous infusions of 8-CCE, but not mldazolam. This 
averslve effect of 8-CCE was~ reversed by RO 15-1788. The 
behavioral effects of 8-CCE in these non-human primates are 
consistent with other data that have shown it to act on 
benzodiazepine receptors, and support the hypothesis that 
8-CCE can be considered an inverse agonist at this receptor. 
The discovery of brain binding sites for the benzodlazepines (1,2) 
spurred the search for potential antagonists of these anxiolytic drugs. One 
of the first non-benzodiazeplnes that was found to bind to benzodiazepine 
receptors was 8-carboline-3-carboxylic acid ethyl ester (8-CCE [3]). It 
reversed the effects of benzodiazepines (4-7) and, in contrast to the more 
recently developed benzodiazeplne antagonists such as Ro 15-1788 (8), had 
actions of its own that were in many instances opposite to those of the 
benzodiazepines. While many benzodiazepines have anti-convulsant activity 
and attenuate the effects of punishment on behavior (e.g. 9,10,11), 8-CCE is 
a proconvulsant in rodents (12-13), a convulsant in squirrel monkeys (14-15), 
and it and related drugs have been shown to enhance the effects of punishment 
(15-16). 8-CCE decreased rates of punished responding and increased rates of 
shock-maintained responding in squirrel monkeys. These effects were opposite 
to the effects of benzodiazepines and were reversed by administration of Ro 
15-1788 which had no effects of its own (15). when given intravenously to 
rhesus monkeys, 8-CCE has been reported to produce apparent anxiety-llke 
effects, including agitation, vocalization and increases in plasma cortlsol, 
epinephrine, norepinephrine, heart rate and blood pressure. These effects 
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were prevented by administration of the benzodiazepine receptor antagonist Ro 
15-1788 (17) and by dlazepam (18). 
Studies in man showed that FG 7142, the ethylamide congener of 8-CCE, 
elicited physiological responses similar to those produced by ~-CCE in 
monkeys. In these subjects, plasma levels of cortlsol as well as heart rate 
and blood pressure were increased (19). In addition, the human subjects gave 
verbal reports of severe anxiety and intense inner tension. 
These data, supported by biochemical information (20), have led to the 
development of a novel classification of drugs that act on the benzodiazepine 
receptor. The anxiolytic benzodiazepines, with punishment attenuating and 
general dlsinhibitory effects, are referred to as benzodiazepine receptor 
agonists. 8-Carbolines that enhance effects of punishment and increase 
autonomic activity are called inverse agonists at the benzodiazepine 
receptor, whereas drugs such as Ro 15-1788, with little intrinsic activity 
but with the capacity to reverse the actions of both the agonists and inverse 
agonists are termed benzodiazepine receptor antagonists (21-23). The concept 
that markedly different drugs can produce such a wide spectrum of effects 
through their interactions at a single receptor is unique in experimental 
pharmacology and deserves extensive scrutiny in pharmacological and 
behavioral systems. 
We report in this paper the results of studies designed to determine 
whether the behavioral effects of 8-CCE in the rhesus monkey are consistent 
with the conceptualization of this drug as an inverse agonist at the 
benzodiazepine receptor. ~-CCE was established as a discriminative stimulus 
in rhesus monkeys, and it was also evaluated for aversive properties by 
examining its capacity to act as a negative reinforcer in primates. Primates 
have a distinct advantage over rodents in the evaluation of ~-CCE, since 
rodents metabolize this drug very quickly (23), while primates apparently do 
not (14). 
Methods 
Discriminative stimulus: Four rhesus monkeys were trained to discriminate a 
subcutaneous injection of i mg/kg 8-CCE from a similar injection of vehicle. 
During daily experimental sessions, these monkeys were seated in primate 
restraining chairs which were placed in isolation chambers equipped with two 
levers, a food receptacle, and a bank of stimulus lights. The monkeys had 
been trained to make thirty consecutive responses (FR 30) on the rightmost of 
the two levers and receive a 300 mg Noyes banana-flavored pellet if they had 
been given 1 mg/kg 8-CCE, 30 minutes earlier. If the injection had been of 
vehicle, responses on the leftmost lever were reinforced on the same 
schedule. A daily session lasted for 2~ minutes or until 5~ food pellets had 
been delivered. During test sessions, 30 consecutive responses on either of 
the two levers resulted in food delivery.. 
A separate group of three monkeys was trained to discriminate the 
effects of i~ mg/kg s.c. methohexital, an ultra short-acting barbiturate. 
These monkeys were trained and tested using the same equipment as with the 
8-CCE monkeys, but by a slightly different procedure, described by Bertalmio 
et al. (24). As shown by Bertalmio et al. (24), there are minimal 
differences in drug effects with these two procedures. A multiple trials 
procedure was used; each trial was 15 min in duration, and as many as six 
trials constituted a daily session. On training days, either an injection of 
10 mg/kg methohexital or a sham injection preceded each trial, and the monkey 
was in a blackout period for the first i~ min of each trial. With the onset 
of the stimulus light, i00 consecutive responses on the injection-appropriate 
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lever resulted in delivery of i~ food pellets. Methohexital was given on the 
penultimate trial of a session, and responding on the methohexital- 
appropriate lever was reinforced on this and the last trial of a session. 
From zero to four sham injection trials could precede the methohexital 
injection on a training day, and six sham injection trials constituted a 
session on occasion. The criterion for testing was that 90% of each trial's 
responses had to be made on the injection- appropriate lever on the session 
before the test session. On test days, i00 consecutive responses on either 
lever were reinforced. The first trial of a test session was preceded by 
administration of saline or of a potential antagonist, and subsequent trials 
were preceded by increasing, cumulative doses of the test drug. 
Aversive Effects: Three monkeys were adapted to restraining harnesses and 
arms that allow them relatively free movement within their individual cages 
and also permitted the passage and protection of intravenous catheters (25). 
The monkeys were prepared, under aseptic conditions, using ketamine and 
pentobarbital anesthesia, with intravenous jugular or femoral catheters. 
During two daily sessions, one in the morning and one in the afternoon, they 
were trained first to press a lever in the presence of a stimulus light and 
receive intravenous infusions of cocaine, then to press the lever and turn 
off infusions of 7 ug/kg/sec histamine. A single response was necessary to 
terminate the infusion for two of the monkeys, while five responses were 
required for the third monkey. An unterminated infusion lasted for 15 sec; 
terminated and unterminated infusions were followed by a five-min light-off 
period. A maximum of 20 infusions could be delivered during each session. 
During particular sessions, saline, the hydrochloride salt of 8-CCE, or 
midazolam were infused instead of histamine. When Ro 15-1788 was given as a 
pretreatment, it was administered subcutaneously, i0 mln before the start of 
the session. 
Drugs: 8-CCE and Ro 15-1788 were suspended in Emulphor, 95% ethanol, and 
water in a ratio of 1:1:8. Doses are expressed as the free base. Midazolam 
maleate was dissolved in water with a few drops of lactic acid added. Sodium 
methohexital and the hydrochloride salt of 8-CCE were dissolved in water. 
The doses of these drugs are expressed as the salts. 
Results 
8-CCE produced dose-related increases in selection of the 
8-CCE-appropriate lever in the monkeys trained to discriminate this drug 
(Fig. IA). These same doses of 8-CCE did not produce methohexital- 
appropriate responses in monkeys trained to discriminate methohexital (Fig. 
IB). In contrast, the short-acting benzodiazepine mldazolam, in doses as 
high as 1 mg/kg, did not produce 8-CCE-approprlate responding in the monkeys 
trained to discriminate 8-CCE (Fig. IA) but did produce drug-approprlate 
responding in the monkeys trained to discriminate methohexital (Fig iB). 
Doses of midazolam above i mg/kg produced response decrements in the 
8-CCE-trained monkeys. 
Midazolam (0.32 mg/kg, given i0 minutes before the session) completely 
prevented the discriminative effects of i mg/kg 8-CCE in two 8-CCE-trained 
monkeys (not shown). Ro 15-1788 (I mg/kg, given i~ minutes before the 
session) competitively antagonized the discriminative effects of 8-CCE in the 
8-CCE-trained monkeys (Fig. IA) and produced a similar shift to the right in 
the discriminative effects of midazolam in two of the three 
methohexital-trained monkeys. A less prononounced shift was observed in the 
third monkey (Fig. IB). 
RO 15-1788 in doses of i0 and 17.8 mg/kg, given 30 minutes before the 
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session, produced 8-CCE-appropriate responding in each of the three monkeys 
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Fig. i 
A. Drug-appropriate responding following subcutaneous administration of 8-CCE 
alone (O, n=4), 8-CCE in combination with 1 mg/kg Ro 15-1788 (0, n=2), Ro 
15-1788 alone (~, n=3), and mldazolam alone (O, n=4) in monkeys trained to 
discriminate the s.c. administration of 1 mg/kg B-CCE. 
B. Dose-effect curves for midazolam ([]), 8-CCE (O), and Ro 15-1788 
(z~) alone, and mldazolam in combination with 1 mg/kg Ro 15-1788 I) in three 
monkeys trained to discriminate the subcutaneous administration of I0 mg/kg 
methohexital from sham injections. Points at "C" in either panel represent 
the values after the control injections. The asterisks indicate data 
obtained in a reduced number of monkeys because animals which showed 
drug-appropriate responding or response suppression at lower doses of the 
administered drug were not tested. 
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cumulative fashion to the methohexital-trained monkeys, produced 
drug-appropriate responding in one of the three monkeys. This was the same 
monkey in whom 1.0 mg/kg Ro 15-1788 was less effective as a midazolam 
antagonist. 
In order to determine whether the behavioral effects of B-CCE can be 
considered to be those of a benzodlazepine inverse agonist, the capacity of 
8-CCE and mldazolam to maintain escape responding was compared. As shown in 
Figure 2, 8-CCE and histamine maintained escape responding, while saline did 
not. Midazolam at infusion rates of 2 or 7 ~g/kg/sec failed to maintain more 
escape behavior than that maintained by saline in all monkeys (not shown). 
Ro 15-1788 (I mg/kg) reduced 8-CCE-malntained escape responding but did not 
greatly affect histamine-maintained escape responding (Fig. 2). 
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Effects of 7 ~g/kg/sec histamine, saline, 2 ~g/kg/sec 8-CCE, and these 
infusion rates of 8-CCE or histamine in combination with subcutaneously 
injected 1 mg/kg Ro 15-1788 on behavior maintained by the termination of 
intravenous infusions of these drugs. Twenty infusions were initiated 
during each session and the ordinate indicates the percentage of trials 
during which the monkey responded and thus escaped from further infusion. 
The abscissa indicates the drug conditions that were used to maintain 
responding. The vertical lines at each bar are the range of the percent 
infusions terminated for that particular drug condition. 
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Discussion 
Rhesus monkeys learned to discriminate the stimulus effects of the 
benzodiazeplne inverse agonist 8-CCE, and the stimulus effects of this drug 
were dissimilar from those of the benzodiazepine agonist midazolam. Monkeys 
trained to terminate intravenous infusions of histamine terminated infusions 
of 8-CCE but not mldazolam. Therefore, 8-CCE, but not midazolam, was a 
negatively reinforcing stimulus under these experimental conditions. Both 
the discriminative and negatively reinforcing effects of 8-CCE were 
antagonized by the benzodiazepine antagonist Ro 15-1788, as was the 
discriminative effect of midazolam. These experiments demonstrate that, 
using objective behavioral procedures in primates, 8-CCE can be shown to act 
on benzodiazeplne receptors to produce effects that are different, and 
apparently opposite to those of a benzodlazeplne agonist, midazolam. 
More support for the opposite nature of 8-CCE and midazolam comes from 
data that demonstrate that mldazolam has positive reinforcing effects that, 
while less than those of methohexital (Winger, unpublished observations) or 
pentobarbital (26), are considerably greater than those of saline. 
If this were the extent of the information about the interactions among 
benzodiazeplnes, 8-carbolines and benzodlazepine antagonists, there would be 
strong parallels between the benzodiazepine receptor system and the opiate 
receptor system. In the opiate class, morphine and ethylketocyclazocine 
(EKC) produce distinctive discriminative stimulus effects in primates (27). 
Morphine maintains self-administration behavior while EKC does not (28) and 
EKC may be aversive under some conditions (Woods et al. In press). The 
effects of morphine and EKC in these behavioral paradigms are reversed by 
opiate antagonists. In the opiate system, morphine and EKC are both 
considered to be opiate agonists, but are thought to act on different classes 
of opiate receptor (29). 
This type of classification does not apply to drugs that act on the 
benzodiazepine receptors however, because of the mutual antagonism of 
benzodlazepine agonists and inverse agonists such as 8-CCE. As described in 
this report, midazolam was able to block the discriminative effects of 8-CCE. 
Although attempts to reverse the discriminative stimulus effects of midazolam 
with 8-CCE failed because administration of effective antagonistic doses of 
8-CCE suppressed responding (Winger, unpublished observation), other studies 
have shown that 8-CCE is an effective antagonist of benzodiazeplnes (4-7). 
This mutual antagonism suggests that 8-CCE and benzodiazepine agonists do not 
produce distinct effects by acting on different receptors in the same system, 
but by acting on the same receptor. The fact that midazolam is a positive 
reinforcer while B-CCE is a negative reinforcer supports the concept of 8-CCE 
as an inverse agonist at this receptor. This is a unique and fascinating 
aspect of the pharmacology of the benzodiazepine receptor complex. 
The data shown here demonstrate another unique feature of the 
benzodlazepine receptor. The drug Ro 15-1788, regarded as a benzodiazepine 
receptor antagonist with few effects of its own (8) has been shown, in some 
species and in some situations, to have actions in common with benzodiazepine 
agonists (30-32). Less frequently, Ro 15-1788 has been shown to have actions 
in common with inverse agonlsts (33). In the experiments shown here, Ro 
15-1788 was, at the same dose, an effective surmountable antagonist of both 
8-CCE and midazolam. At larger doses it produced 8-CCE-llke stimulus effects 
in each of the 8-CCE-trained monkeys, and methohexital-like stimulus effects 
in only one of the methohexltal-trained monkeys. In this system, Ro 15-1788 
appeared to act as a benzodiazepine antaqonlst, and, at larger doses, as a 
benzodiazepine inverse agonist. 
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Nielsen et al. (34) established the discriminative stimulus effects of 
the convulsant beta-carboline DMCM (6,7-dimethyl-4-ethyl-8-carboline- 
3-carboxylate) in rats. Ro 15-1788 (80 mg/kg) produced 57% responding on the 
DMCM-appropriate lever. Given as a pretreatment, Ro 15-1788 reduced the 
capacity of DMCM to produce drug-appropriate responding to about 50% at three 
doses (20, 40 and 8o mg/kg). These data suggest both antagonist and inverse 
agonlst effects of RO 15-1788, but, in these experiments, neither of these 
effects was complete. Other investigators have suggested that the 
agonist-antagonist profile of Ro 15-1788 may change as a function of the dose 
of benzodiazepine used to establish a drug discrimination (35). Thus, the 
discriminative stimulus properties of Ro 15-1788, and its relative effects as 
an agonist, antagonist or inverse agonlst, seem determined by a variety of 
variables, including dose of Ro 15-1788, as shown in the current study, type 
and dose of the training drug, perhaps as well as the species and particular 
paradigm employed. 
The experiments described demonstrate that, although both the 
discriminative and reinforcing stimulus properties of 8-CCE are mediated 
through the benzodiazeplne receptor, they are different or in the opposite 
direction from the discriminative and reinforcing stimulus properties of 
midazolam. These behavioral studies may be very useful in studying the 
similarity among substances related to anxiety, both those with exogenous and 
those with endogenous origins. In addition, 8-CCE-induced effects may 
provide a pharmacological reference for studying environmental or historical 
factors that modify anxiety. 
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